Novartis AG
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Lucentis (ranibizumab — Wet AMD, Ex-US) by Year
Lucentis (ranibizumab — Wet AMD, Ex-US) ($M)
Novartis Lucentis (ranibizumab — Wet AMD, Ex-US): $643M in FY2025, down 38.4% from a year earlier. That is the lowest of the 9 years on record here.
Where the FY2025 figure comes from
“|| Lucentis | 643 | 1 044 | -38 | -40”
Source: Novartis Form 6-K (0001114448-26-000007) ↗
Reported in Form 6-K & Form 20-F.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Lucentis (ranibizumab — Wet AMD, Ex-US) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 643 | -38.4% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2024 | Dec 31, 2024 | 1,044 | -29.2% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2023 | Dec 31, 2023 | 1,475 | -21.3% | Novartis Form 6-K (0001370368-25-000007) ↗ |
| FY2022 | Dec 31, 2022 | 1,874 | -13.2% | Novartis Form 6-K (0001370368-24-000007) ↗ |
| FY2021 | Dec 31, 2021 | 2,160 | +11.7% | Novartis Form 6-K (0001370368-23-000008) ↗ |
| FY2020 | Dec 31, 2020 | 1,933 | -7.3% | Novartis Form 6-K (0001370368-21-000008) ↗ |
| FY2019 | Dec 31, 2019 | 2,086 | +2.0% | Novartis Form 6-K (0001370368-21-000008) ↗ |
| FY2018 | Dec 31, 2018 | 2,046 | +8.4% | Novartis Form 6-K (0001370368-20-000007) ↗ |
| FY2017 | Dec 31, 2017 | 1,888 | – | Novartis Form 6-K (0001370368-19-000006) ↗ |
Breakdown
What makes up lucentis (ranibizumab — Wet AMD, Ex-US)
Cite this data
StockData. (2026). Novartis Lucentis (ranibizumab — Wet AMD, Ex-US) ($M), annual FY2017–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-lucentis
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.